Orexigen Resurrects Contrave With New Trial Agreement With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech breathes new life into its obesity program now that it has reached agreement with FDA on a two-year cardiovascular safety study for Contrave.
You may also be interested in...
Lorcaserin Safety Questions Can Be Answered In Post-Market Study, Panel Tells FDA
FDA’s Endocrinologic and Metabolic Advisory Committee backs approval of Arena’s weight-loss drug 18 to 4 with one abstention. Uncertainty over the risk for heart disease remains a prime concern for panel members.
With SPA Finalized, Orexigen To Begin CV Outcomes Study For Contrave In Second Quarter
The company expects to be able to re-file the NDA for its obesity candidate by 2014, after 87 major adverse events were recorded in the 10,000-patient, placebo-controlled safety trial.
Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
New developments for Vivus’ weight loss drug Qnexa may mean that the regulatory environment for obesity treatments could be improving.